Skip to main content

Table 4 Change rate in each marker after treatment

From: The effect of dapagliflozin treatment on epicardial adipose tissue volume

  Dapagliflozin (n = 20) Conventional therapy (n = 20) p value, dapagliflozin vs. conventional
Δ body weight (kg) − 2.9 ± 3.4** 0.2 ± 2.4 0.01
Lipid profile
 ΔLDL (mg/dl) 6.0 ± 26.5 − 1.0 ± 13.7 0.41
 ΔTG (mg/dl) − 33.4 ± 66.2* 3.2 ± 19.0 0.07
 ΔHDL (mg/dl) 5.1 ± 15.2 − 0.7 ± 4.8 0.21
 ΔTG/HDL − 0.8 ± 1.7** 0.2 ± 0.8 0.06
Glycemic marker
 ΔHbA1c (%) − 0.41 ± 0.21** − 0.19 ± 0.25 0.22
 ΔHOMA-IR − 0.99 ± 1.90** − 0.42 ± 0.86* 0.64
 ΔiHOMA2%S 65.7 ± 70.9** 42.2 ± 61.1 0.36
ΔBNP (pg/ml) − 24 ± 83 − 12 ± 54 0.68
ΔAlb/Cre (mg/g·CRE) − 3.8 ± 29.6 8.7 ± 43.2 0.38
  1. LDL low density lipoprotein cholesterol, HDL high density lipoprotein cholesterol, HOMA-IR homeostatic model assessment insulin resistance, iHOMA-2 interactive 24-variable model homeostatic model assessment insulin resistance-2, BNP brain natriuretic peptide, Alb/Cre ratio albumin/creatinine ratio
  2. Data are expressed as mean ± SD; ** p < 0.05 compared with baseline of each group, * p < 0.1 compared with baseline of each group